eXoZymes (NASDAQ:EXOZ) Stock: Insider Damien Alan Perriman Sells 3,729 Shares

eXoZymes Inc. (NASDAQ:EXOZ) insider Damien Alan Perriman sold 3,729 shares of the business’s stock in a transaction dated Monday, October 12th. The shares were sold at an average price of $5.21, for a total value of $19,428.09. Following the completion of the transaction, the insider owned 28,692 shares in the company, valued at $149,485.32. This trade represents a 11.50% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

eXoZymes Stock Up 1.3%

EXOZ opened at $3.80 on Wednesday. eXoZymes Inc. has a 52 week low of $3.24 and a 52 week high of $18.40. The business has a 50 day moving average price of $5.86 and a two-hundred day moving average price of $7.86.

eXoZymes (NASDAQ:EXOZ) last announced its earnings results on Thursday, August 13th. The company reported ($0.33) earnings per share for the quarter. As a group, equities analysts expect that eXoZymes Inc. will post -1.19 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of eXoZymes in a research report on Wednesday, August 26th. Zacks Research raised shares of eXoZymes to a “hold” rating in a research note on Friday, October 2nd. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, eXoZymes currently has an average rating of “Reduce”.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in eXoZymes stock. BlackRock Inc. acquired a new stake in eXoZymes Inc. (NASDAQ:EXOZ) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 9,610 shares of the company’s stock, valued at approximately $81,000. BlackRock Inc. owned 0.10% of eXoZymes as of its most recent SEC filing.

eXoZymes Company Profile

eXoZymes, Inc is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.